Sarah Gheuens - 02 Dec 2021 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Chief Medical Officer
Signature: /s/ William Cook, as attorney-in-fact for Sarah Gheuens
Issuer symbol: AGIO
Transactions as of: 02 Dec 2021
Net transactions value: -$8,680
Form type: 4
Filing time: 07 Dec 2021, 15:18:52 UTC
Previous filing: 10 Sep 2021
Next filing: 14 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+834	+24%	$0.000000	4,296	02 Dec 2021	Direct	F1
transaction	AGIO	Common stock	Tax liability	$8,680	-248	-5.8%	$35.00	4,048	02 Dec 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Restricted stock units	Options Exercise	$0	-834	-50%	$0.000000	833	02 Dec 2021	Common stock	834		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2	The restricted stock units were granted on December 2, 2019. Beginning on December 2, 2020, the shares underlying the restricted stock units will vest in three equal annual installments.